Tag: PharmD

Poster-Quality of Life and Outcomes

Assessing Presence of MS-Related Symptoms As a Proxy for Disease Severity in Multiple Sclerosis Using Administrative Claims Data

Background: Healthcare claims data lack clinically relevant variables such as disease severity. Objectives: Assess multiple sclerosis...

Read More

Poster-Quality of Life and Outcomes

Clinical and Economic Impact of Employees Who Are Care Partners of Patients with Multiple Sclerosis

Background: Historically, there has been limited research on care partners of patients with multiple sclerosis (MS). Employers, health care...

Read More

Poster-Quality of Life and Outcomes

Assessing Patient-Reported Outcomes and Pharmacist Interventions in Multiple Sclerosis within an Integrated Care Center

Background: Patient-reported outcomes (PROs) responses can be used to measure patients’ health status, functioning, quality of life, and...

Read More

Poster-Quality of Life and Outcomes

Patient Reported Outcomes from Pharmacist-Led Multiple Sclerosis Assessments in a Specialty Pharmacy Setting

Background: Disease-modifying therapy (DMT) has demonstrated benefits for patients in reducing relapse rates, disability progression, and...

Read More

Poster-Programs

Continued Expansion of a Multiple Sclerosis Pharmacy Program

Background: Kaiser Permanente Washington (KPWA) launched a Multiple Sclerosis (MS) Pharmacy Program in June 2014 to support patients on...

Read More

Poster-Multidisciplinary Care

Integrated Clinic-Based Pharmacist Impact on Time to Fingolimod Treatment Initiation

Background: Multiple Sclerosis (MS) has no cure and causes irreversible damage to the brain and spinal cord leading to physical and...

Read More

Poster-Disease-modifying Therapy

Efficacy and Safety of Eculizumab in Patients with Neuromyelitis Optica Spectrum Disorder Previously Treated with Rituximab: Findings from Prevent

Background: In PREVENT, eculizumab was associated with a significant reduction in relapse risk versus placebo and was well tolerated. In...

Read More

Poster-Disease-modifying Therapy

Treatment Persistence, Safety, Tolerability, and Effectiveness of Diroximel Fumarate in the Real-World: Design of the Phase 4 Experience–US Study

Background: Diroximel fumarate (DRF) is an oral fumarate approved in the United States (US) for relapsing multiple sclerosis (MS). DRF...

Read More

Poster-Disease-modifying Therapy

Psoriasis in Multiple Sclerosis Patients Treated with Disease Modifying Therapies

Background: Psoriasis may be more common in people living with multiple sclerosis (PwMS) than in the general population. Some pathways...

Read More

Poster-Disease-modifying Therapy

Real-World Safety and Effectiveness of Delayed-Release Dimethyl Fumarate in Relapsing Multiple Sclerosis Patients: Interim Results from Esteem

Background: Dimethyl fumarate (DMF) demonstrated strong efficacy and a favorable benefit–risk profile in patients with relapsing-remitting...

Read More